Wedbush raised the firm’s price target on Vera Therapeutics to $21 from $16 and keeps a Neutral rating on the shares. Vera’s atacicept demonstrated continued eGFR stabilization at week 72 in the open-label extension phase of the Phase 2b ORIGIN study, the analyst tells investors in a research note. The key unanswered question remains how the APRIL-targeted agents will differentiate in final data sets, the firm says.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on VERA:
- Vera Therapeutics Reports Positive Phase 2b ORIGIN Trial Results
- Vera Therapeutics Announces Promising 72-Week Trial Results
- Vera Therapeutics to host research and development day
- Vera Therapeutics’ atacicept shows positive Phase 2b data in IgA nephropathy
- Vera Therapeutics Presents Positive 72-Week Data Showing eGFR Stabilization in the Phase 2b ORIGIN Clinical Trial OLE in IgA Nephropathy